SC 38249 [RS)-1-(2,3-bis-[(4-methoxyphenyl)methoxy]propyl)-1H-
imidazole) caused dose-related inhibition of
collagen-induced
thromboxane A2 formation in human platelet rich plasma (IC50: 9.9 +/- 1.0 microM) accompanied by a dose-dependent increase in plasma
PGE2. Broad inhibitory activity was evident against human platelet aggregatory and secretory responses in vitro. IC50 values of 11.9 +/- 1.9 microM (0.64 mM
arachidonic acid), 18.3 +/- 3.8 microM (0.5 microgram ml-1
collagen) and 37.6 +/- 6.1 microM (25 nM
Paf-acether) were obtained against maximum increase in PRP light transmission achieved by each agonist. Although less potent,
SC 38249 retained significant inhibitory activity against PRP responses induced by a higher (3.0 micrograms ml-1) concentration of
collagen (IC50: 272.5 +/- 24.6 microM), and against
Paf-acether-induced responses in PRP pre-treated with 10 microM
indomethacin (I.C.50: 192.0 +/- 16.1 microM). Experimental animal studies confirmed the in vitro anti-aggregatory efficacy of
SC 38249, since significant inhibitory activity was observed against
Paf-acether and
ADP-induced responses in dog PRP ex vivo, anti-
Forssman antibody-induced
thrombocytopenia in anaesthetized guinea pigs, and
collagen-induced intravascular aggregation in anaesthetized rabbits. Thus,
SC 38249 is a novel
thromboxane synthase inhibitor which possesses interesting anti-aggregatory properties which cannot wholly be attributed to prevention of platelet
thromboxane A2 formation.